Results 351 to 360 of about 1,515,008 (404)

Low Density Lipoproteins and Hypercholesterolemia

1989
Coronary and vascular disease of atherosclerotic origin are the main causes of death and at the same time the most frequent reasons for early invalidity in the Federal Republic of Germany and other industrialized nations. In particular, coronary heart disease (CHD) is the major cause of death in middle-aged men.
G, Assmann, H, Funke, G, Schmitz
openaire   +2 more sources

Low-density lipoprotein heterogeneity

Baillière's Clinical Endocrinology and Metabolism, 1995
As a key feature of the ALP, a raised level of small, dense LDL forms part of what is potentially the most common collection of lipoprotein abnormalities to influence the risk of CHD in the general population. The consistency of the association between a prevalence of small, dense LDL and increased risk of CHD is impressive, though the practical ...
openaire   +2 more sources

Low-density lipoprotein and oxidised low-density lipoprotein: Their role in the development of atherosclerosis

Pharmacology & Therapeutics, 1997
Oxidation of low-density lipoprotein (LDL) may be implicated in the development of atherosclerotic disease. Oxidised LDL is taken up more readily by monocyte-derived macrophages than LDL. Antibodies to oxidised LDL are found in atherosclerotic lesions, Increased risk of ischaemic heart disease is associated with a preponderance of small dense LDL ...
openaire   +2 more sources

Low-density lipoprotein oxidation.

Italian heart journal : official journal of the Italian Federation of Cardiology, 2001
Free radical mediated oxidation of low-density lipoproteins (LDL), which has been extensively studied in the last two decades, plays a central role in the development of the atherosclerotic plaque. Oxidation involves the lipid moiety of LDL in a chain reaction mechanism.
IULIANO, Luigi, MICHELETTA F, VIOLI, Francesco   +2 more
openaire   +2 more sources

Modified Low-Density Lipoproteins and High-Density Lipoproteins

Pathophysiology of Haemostasis and Thrombosis, 2006
It has long been known that the oxidative state of the various plasma lipoproteins modulates platelet aggregability, thereby contributing to atherogenesis. Low-density lipoprotein (LDL), occurring in vivo both in the native and oxidised forms, interacts directly with platelets, by binding to specific receptors.
Elisabeth Koller, Ivo Volf, Aner Gurvitz, Franz Koller   +3 more
openaire   +1 more source

Low-density Lipoproteins in Atherogenesis

2000
It is well established that high levels of plasma cholesterol, particularly those associated with low-density lipoprotein (LDL), increase the risk of developing atherosclerosis. It is also clear that lowering plasma cholesterol levels can arrest or even reverse the progression of the disease [1,2].
openaire   +1 more source

High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein

Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
Oxidatively modified low-density lipoprotein (LDL), generated as a result of incubation of LDL with specific cells (e.g., endothelial cells, EC) or redox metals like copper, has been suggested to be an atherogenic form of LDL. Epidemiological evidence suggests that higher concentrations of plasma high-density lipoprotein (HDL) are protective against ...
S, Parthasarathy, J, Barnett, L G, Fong
openaire   +2 more sources

Inhibition of Low-Density Lipoprotein and High-Density Lipoprotein Oxidation by Raloxifene

Journal of Women's Health, 2004
Raloxifene (RX), a selective estrogen receptor modulator (SERM), has demonstrated hypolipidemic and in vitro antioxidant properties. In the pathogenesis of atherosclerosis, the oxidative modification of low-density lipoprotein (LDL) is implicated to play a crucial role.In this study, we investigated the antioxidant properties of RX during in vitro LDL ...
Ulrike, Resch, Viktoria, Mellauner, Alexandra, Budinsky, Helmut, Sinzinger   +3 more
openaire   +2 more sources

Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?

Current Atherosclerosis Reports, 2007
Lowering low-density lipoprotein cholesterol is the cornerstone of risk modification in patients with established coronary artery disease. Considerable attention is currently focused on developing pharmacologic agents that promote the biologic activity of high-density lipoprotein.
Stephen J, Nicholls, E Murat, Tuzcu, Steven E, Nissen   +2 more
openaire   +2 more sources

Low-Density Lipoprotein Receptor-Related Proteins

Encyclopedia of Molecular Pharmacology, 2021
M. Narita, Dave M. Holtzman, Alan, L., Schwartz, G. Bu   +5 more
semanticscholar   +1 more source